Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy (Q42845478)

8 November 2017

title

Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy (English)

1 reference

non-small-cell lung carcinoma

8 November 2017

main subject

1 reference

Nagahiro Saijo

1 reference

8 November 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Nature Reviews Clinical Oncology

8 November 2017

published in

1 reference

8 November 2017

1 reference

8 November 2017

1 reference

8 November 2017

page(s)

618-619

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.168

10.1038/NRCLINONC.2010.168

31 March 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

8 November 2017

1021141382

0 references

1 reference